Peanut Allergy - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Peanut Allergy - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Peanut Allergy - Pipeline Review, H2 2014', provides an overview of the Peanut Allergy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peanut Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peanut Allergy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peanut Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Peanut Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Peanut Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peanut Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peanut Allergy
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peanut Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peanut Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Peanut Allergy - Overview 8
Pipeline Products for Peanut Allergy - Comparative Analysis 9
Peanut Allergy - Therapeutics under Development by Companies 10
Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 11
Peanut Allergy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Peanut Allergy - Products under Development by Companies 14
Peanut Allergy - Products under Investigation by Universities/Institutes 15
Peanut Allergy - Companies Involved in Therapeutics Development 16
BioTech Tools 16
DBV Technologies SA 17
HAL Allergy BV 18
Anergis SA 19
Immunomic Therapeutics, Inc. 20
Tunitas Therapeutics, Inc. 21
Perosphere Inc. 22
Sementis Ltd 23
Allergen Research Corporation 24
Peanut Allergy - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
DBV-712 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Peanut Allergy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HALMPE-1 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ARA-LAMP-Vax - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein for Peanut Allergy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pnut-ASIT - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DN-1017 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Vaccine for Peanut Allergy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Recombinant Vector Vaccine for Peanut Allergy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Vaccine for Peanut Allergy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PER-1080 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Peanut Allergy - Recent Pipeline Updates 44
Peanut Allergy - Dormant Projects 49
Peanut Allergy - Discontinued Products 50
Peanut Allergy - Product Development Milestones 51
Featured News & Press Releases 51
Jun 10, 2014: Five Scientific Communications at the European Academy of Allergy and Clinical Immunology Congress Further Support DBV's EPIT Disease Modifying Effect 51
Apr 16, 2014: DBV Announces the First reported case of a long term sustained effect of Peanut desensitization after Epicutaneous Immunotherapy with Viaskin at the French Congress of Allergy 51
Mar 17, 2014: DBV Technologies Provides VIPES Update 52
Feb 27, 2014: Allergen Research Initiates Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy 53
Oct 24, 2013: NIH-sponsored Consortium of Food Allergy Research starts a Phase II clinical study with DBV Technologies' Viaskin Peanut in the treatment of peanut allergy 54
Oct 15, 2013: DBV Provides Safety Update on Viaskin Peanut 54
Sep 04, 2013: DBV Technologies initiates a long-term follow-up study of Viaskin Peanut 55
Jul 08, 2013: DBV Technologies completes enrollment of Phase IIb VIPES study, the first-ever global trial in desensitization to peanut allergy 55
Jun 20, 2013: DBV Technologies Announces Viaskin Peanut Demonstrates Strong Efficacy Trend In Severely Peanut-Allergic Children In 18-Month Results Of ARACHILD Pilot Study 56
May 07, 2013: DBV Technologies And Mount Sinai Hospital Form Research Collaboration 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for Peanut Allergy, H2 2014 8
Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Peanut Allergy - Pipeline by BioTech Tools, H2 2014 16
Peanut Allergy - Pipeline by DBV Technologies SA, H2 2014 17
Peanut Allergy - Pipeline by HAL Allergy BV, H2 2014 18
Peanut Allergy - Pipeline by Anergis SA, H2 2014 19
Peanut Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2014 20
Peanut Allergy - Pipeline by Tunitas Therapeutics, Inc., H2 2014 21
Peanut Allergy - Pipeline by Perosphere Inc., H2 2014 22
Peanut Allergy - Pipeline by Sementis Ltd, H2 2014 23
Peanut Allergy - Pipeline by Allergen Research Corporation, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Peanut Allergy Therapeutics - Recent Pipeline Updates, H2 2014 44
Peanut Allergy - Dormant Projects, H2 2014 49
Peanut Allergy - Discontinued Products, H2 2014 50